Core Viewpoint - The company Insilico Medicine (3696.HK) has seen significant stock price increases, reaching a new high of 66.5 HKD and a market capitalization of 38 billion HKD, driven by multiple strategic partnerships in early January 2023 [1] Group 1: Strategic Partnerships - On January 5, the company entered an 888 million USD research collaboration with Servier, focusing on innovative anti-tumor therapies [1] - On January 20, a partnership was established with Shenzhen Hengtai Biopharmaceutical for the ISM8969 project, aimed at accelerating global development, with both parties holding 50% equity [1] - On January 27, a collaboration worth over 931 million HKD was formed with Qilu Pharmaceutical, concentrating on novel small molecule drug design and optimization for metabolic diseases [1] Group 2: Clinical Development and Pipeline - The company has extensive experience in AI-driven drug development for oncology, with a pipeline covering various cancer indications [1] - The potential best-in-class TEAD inhibitor ISM6331 and MAT2A inhibitor ISM3412 have both initiated global multi-center Phase I clinical trials [1] - Four oncology projects have been fully or partially licensed to partners, with related Phase I clinical trials progressing steadily [1]

Core Viewpoint - The stock of Insilico Medicine (03696) has seen a significant increase, reaching a new high of HKD 61.30, with a current price of HKD 60.10, reflecting a 5.44% rise and a trading volume of HKD 61.32 million [1][4]. Group 1: Company Developments - Insilico Medicine has entered into a long-term R&D collaboration with Schwabe to develop anti-tumor drugs using its AI platform, Pharma.AI [1][4]. - The company has extensive experience in AI-driven tumor drug development and has established a pipeline covering various cancer indications [1][4]. - Two specific inhibitors, TEAD inhibitor ISM6331 and MAT2A inhibitor ISM3412, have initiated global multi-center Phase I clinical trials, with four additional tumor projects licensed out [1][4]. Group 2: Market Position and Financials - According to Zhongyou Securities, Insilico Medicine has a prestigious base of cornerstone investors and is a leader in the AI drug discovery field [1][4]. - The Pharma.AI platform has incubated over 20 assets in clinical or IND application stages, with three assets licensed to international pharmaceutical companies, totaling a contract value of up to USD 2.1 billion, alongside one asset in Phase II development [1][4].

Core Viewpoint - Incyte Corporation (03696) has seen its stock price rise over 7%, reaching a new high of 61.3 HKD, driven by a long-term R&D collaboration with Sivea to develop anti-tumor drugs using the AI platform Pharma.AI [1] Group 1: Company Developments - Incyte has extensive experience in AI-driven tumor drug development and has established a pipeline covering various cancer indications [1] - The company has initiated global multi-center Phase I clinical trials for two drugs: TEAD inhibitor ISM6331 and MAT2A inhibitor ISM3412, with four additional tumor projects already licensed out [1] Group 2: Financial and Market Position - According to Zhongyou Securities, Incyte's strong investor base positions it as a leader in the AI drug discovery field [1] - The Pharma.AI platform has incubated over 20 assets in clinical or IND application stages, with three assets licensed to international pharmaceutical companies, totaling contract values up to 2.1 billion USD, alongside one asset in Phase II development [1]

Group 1 - The core point of the article is that Insilico Medicine has announced its first business development deal after going public, partnering with Sivea for a long-term collaboration in anti-tumor drug development, valued at $888 million [2] - Insilico Medicine will utilize its proprietary AI platform, Pharma.AI, to focus on challenging targets in oncology, while Sivea will share the development costs and lead clinical validation and commercialization [2] - Sivea's oncology business is a key area, with projected sales of €1.43 billion for the fiscal year 2023-2024, representing a 33% year-on-year growth and accounting for 24.2% of the group's total revenue [2] Group 2 - Insilico Medicine has established a pipeline covering various cancer indications, with two inhibitors, ISM6331 and ISM3412, currently in global Phase I clinical trials [2] - The company has secured software licensing agreements with 13 of the top 20 global pharmaceutical companies and has formed three pipeline collaborations with companies like Exelixis and Menarini, with a total deal value of approximately $2.1 billion [3] - As of January 5, Insilico Medicine's stock closed at HKD 37.38 per share, with a total market capitalization of HKD 20.84 billion [4]

Core Viewpoint - The collaboration between Insilico Medicine and Servier, valued at $888 million, aims to leverage AI-driven drug discovery for innovative oncology therapies [1] Group 1: Partnership Details - Insilico Medicine has entered a research collaboration with Servier, totaling $888 million, focusing on the discovery and development of innovative anti-cancer therapies [1] - Insilico is eligible for up to $32 million in upfront and milestone payments, while Servier will co-fund R&D costs and lead clinical validation and commercialization [1] Group 2: AI Integration and Efficiency - Insilico Medicine has significantly improved early-stage drug development efficiency by integrating AI and automation, reducing the average time from project initiation to candidate nomination to 12-18 months [2] - The company has nominated 20 preclinical candidates between 2021 and 2024, compared to the traditional average of 4.5 years for early drug development [2] - Each project requires the synthesis and testing of approximately 60-200 molecules, showcasing a streamlined approach to drug discovery [2] Group 3: Pipeline and Clinical Trials - Insilico has established a pipeline of oncology projects with various cancer indications, including promising candidates ISM6331 and ISM3412, which are in global Phase I clinical trials [1] - The company has also licensed out four oncology projects, with ongoing Phase I clinical trials progressing steadily [1]

Core Insights - The article discusses a significant research and development collaboration between Insilico Medicine and Servier, valued at $888 million, focusing on innovative oncology therapies [3][4] - This partnership marks the first major biopharmaceutical business development deal of 2026, highlighting the commitment of both companies to leverage advanced technology in addressing unmet medical needs [4] Summary by Sections - **Collaboration Details** - Insilico Medicine will receive up to $32 million in upfront and milestone payments while leading the discovery and development of potential drug candidates using its AI technology [3] - Servier will co-fund the research and lead subsequent clinical validation and commercialization efforts [3] - **Strategic Importance** - The collaboration showcases Insilico's "Pharma.AI" platform's potential, which transforms drug development into a more efficient and controllable process through generative AI [5] - Insilico has validated its capabilities in oncology, with multiple projects advancing to clinical stages, including ISM6331 and ISM3412, both of which are in global Phase I trials [5] - **Broader Impact and Partnerships** - Since 2020, Insilico has established a vast network of partnerships, securing numerous AI-driven R&D collaborations and pipeline licenses, with potential total values reaching up to $2.1 billion [6] - Collaborations with major pharmaceutical companies like Sanofi and Eli Lilly further validate Insilico's AI platform's adaptability and value creation across various disease areas [6]

Core Insights - The collaboration between Insilico Medicine and Servier, valued at $888 million, marks a significant advancement in the AI drug development sector, focusing on challenging oncology targets and innovative therapies [1] - This partnership highlights the transition of AI in pharmaceuticals from concept validation to a new cycle of value realization, emphasizing the potential of Insilico's Pharma.AI platform [1] Financial Aspects - Insilico Medicine is eligible for an upfront payment of up to $32 million and milestone payments as part of the agreement [1] - The collaboration is seen as a key milestone following Insilico's successful IPO, which was characterized by an oversubscription of 1,427 times in the public offering, raising over HKD 32.83 billion [3] Strategic Partnerships - Insilico has established a broad global network since 2020, forming numerous AI-driven research collaborations and pipeline licenses, including partnerships with major pharmaceutical companies like Sanofi and Eli Lilly [4][5] - The collaboration with Servier is expected to leverage Insilico's AI capabilities and Servier's global commercialization strengths, creating synergistic value [2] Market Performance - Insilico's stock has shown strong performance post-IPO, reflecting market optimism regarding the "AI + biopharma" landscape [3] - The involvement of top-tier investors such as Eli Lilly, Tencent, and Temasek indicates strong capital backing and confidence in the AI drug development sector [3] Future Outlook - The partnership and financial achievements signal a shift in the industry towards deeper commercialization of AI technologies in drug development, with a focus on clinical trial success rates as the ultimate measure of efficacy [6] - The ongoing challenge for Insilico will be to validate the effectiveness of AI-driven drug candidates in clinical settings, moving from early-stage development to therapeutic validation [6]

Core Insights - The collaboration between Insilico Medicine and Servier, valued at $888 million, marks a significant advancement in the AI-driven pharmaceutical sector, focusing on challenging oncology targets and innovative therapies [1][2] - This partnership highlights the transition of AI in drug development from concept validation to a new cycle of value realization, emphasizing the potential of Insilico's Pharma.AI platform [1][6] Group 1: Partnership Details - The agreement allows Insilico to receive up to $32 million in upfront and milestone payments, leveraging its AI technology to identify and advance drug candidates [1] - Servier will share the R&D costs and lead the clinical validation and commercialization of promising drug candidates globally [1] Group 2: Market Performance - Insilico Medicine's IPO on December 30, 2025, was highly successful, with a subscription rate of approximately 1427 times for the public offering, raising over HKD 328.3 billion [3] - The strong backing from top-tier investors, including Eli Lilly, Tencent, and Temasek, reflects a high consensus on the AI pharmaceutical sector's potential [3] Group 3: Strategic Collaborations - Since 2020, Insilico has established a vast network of global partnerships, achieving multiple AI-driven R&D collaborations and pipeline licenses, with total potential values reaching up to $2.1 billion [4] - Collaborations with major pharmaceutical companies like Sanofi and Eli Lilly further enhance Insilico's capabilities in drug development [4] Group 4: Future Challenges - Despite the promising developments, the true test for AI in drug development will be the clinical trial success rates, as the industry shifts focus from early-stage research to efficacy validation [6] - The upcoming years will be crucial in determining whether AI can effectively disrupt traditional drug development timelines and success rates [6]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 INSILICO MEDICINE InSilico Medicine Cayman TopCo 英矽智能 （於開曼群島註冊成立的有限公司） （股份代號：3696） 有關與施維雅達成多年期抗腫瘤藥物研發合作之自願公告 本公告乃由英矽智能（「本公司」，連同其附屬公司統稱「本集團」）自願作出。 英矽智能在人工智能驅動的腫瘤藥物研發方面擁有豐富經驗，公司已建立起覆 蓋多種癌症適應症、兼具中度新穎機制與成熟機制的腫瘤管線。其中，具潛力 成為同類最佳(best-in-class)療法的泛TEAD抑制劑ISM6331以及MAT2A抑制劑 ISM3412，均已啟動全球多中心I期臨床試驗。此外，公司還有四個腫瘤專案已全 部或部分對外授權予合作夥伴，相關I期臨床試驗正穩步推進中。 本公司謹此知會隨附新聞稿的本公司股東及潛在投資者，本集團已與一家由基金 會管理的全球獨立製藥公司施維雅達成多年期研發合作。該合作價值高達8.88 ...